Pharmacotherapeutics
4th Edition By Virginia – Test Bank
If You Want To Purchase This Test Bank Click The Link Below
https://booksforexams.com/product/pharmacotherapeutics-for-advancedpractice-4th-edition-by-virginia-test-bank/
Complete Test Bank With Answers
Sample Questions Posted Below
Chapter3.ImpactofDrugInteractionsandAdverseEventsonTherapeu tics
MULTIPLECHOICE
1. Whichofthefollowingpatientswouldbeathigherriskofexperiencingadve rsedrugreactions(ADRs):
a. A32-year-oldmale
b. A22-year-oldfemale
c. A3-month-oldfemale
d. A48-year-oldmale
ANS:C PTS:1
2. InfantsandyoungchildrenareathigherriskofADRsdueto:
a. Immaturerenalfunctioninschool-agechildren
b. Lackofsafetyandefficacystudiesinthepediatricpopulation
c. Children’sskinbeingthickerthanadults,requiringhigherdosageso ftopicalmedication
d. Infantboyshavingahigherproportionofmusclemass,leadingtoahi ghervolumeofdistribution
ANS:B PTS:1
3. TheelderlyareathighriskofADRsdueto:
a. Havinggreatermusclemassthanyoungeradults,leadingtohigher volumeofdistribution
b. Theextensivestudiesthathavebeenconductedondrugsafetyinthi sagegroup
c. Thebloodbrainbarrierbeinglesspermeable,requiringhigherdosestoachiev etherapeuticeffect
d. Age-relateddecreaseinrenalfunction
ANS:D PTS:1
4. Thetypeofadversedrugreactionthatistheresultofanunwantedbutother wisenormalpharmacologicalactionofadruggivenintheusualtherapeuti cdosesis
a. TypeA
b. TypeB
c. TypeC
d. TypeD
ANS:A PTS:1
5. DigoxinmaycauseaTypeAadversedrugreactiondueto:
a. Idiosyncraticeffects
b. Itsnarrowtherapeuticindex
c. Beingateratogen
d. Beingacarcinogen
ANS:B PTS:1
6. Changesintheindividualpharmacokineticparametersofadsorption,dist ribution,oreliminationmayresultinhighconcentrationsofthedrugintheb ody,leadingtowhichtypeofadversedrugreaction?
a. TypeA
b. TypeC
c. TypeD
d. TypeE
ANS:A PTS:1
7. AccordingtotheWorldHealthOrganizationClassification,TypeBadverse reactionsare:
a. Whenadrugisateratogen
b. Whenadrugiscarcinogenic
c. AdelayedADR,suchasrenalfailure
d. Anallergicoridiosyncraticresponse
ANS:D PTS:1
8. SarahdevelopedarashafterusingatopicalThisisaType allergicdrugreaction.
a. I
b. II
c. III
d. IV
ANS:D PTS:1
9. ApatientmaydevelopneutropeniafromusingtopicalSilvadeneNeutrope niaisa(n):
a. Cytotoxichypersensitivityreaction
b. Immunecomplexhypersensitivity
c. Immediatehypersensitivityreaction
d. Delayedhypersensitivityreaction
ANS:A PTS:1
10. Anaphylacticshockisa:
a. TypeIreaction,calledimmediatehypersensitivityreaction
b. TypeIIreaction,calledcytotoxichypersensitivityreaction
c. TypeIIIallergicreaction,calledimmunecomplexhypersensitivity
d. TypeIVallergicreaction,calleddelayedhypersensitivityreaction
ANS:A PTS:1
11. Jameshashypothalamic-pituitaryadrenalaxissuppressionfromchronicprednisone(acorticosteroid)Heisa triskforwhattypeofadversedrugreaction?
a. TypeB
b. TypeC
c. TypeE
d. TypeF
ANS:B PTS:1
12. Thetreatmentforapatientwhoexperienceshypothalamicpituitaryadrenalaxissuppressionwhiletakingthecorticosteroidprednisone,aTyp eCadversedrugreaction,isto:
a. Immediatelydiscontinuetheprednisone
b. Administerepinephrine
c. Slowlytaperthepatientoffoftheprednisone
d. Monitorforlong-termeffects,suchascancer
ANS:C PTS:1
13. TheACEinhibitorlisinoprilTeratogenscauseType adversedrugreaction.
a. A
b. B
c. C
d. D
ANS:D PTS:1
14. CardiacdefectsareaknownTypeDadversedrugreactiontoLithium causesaTypeDadversedrugreactionbecauseitis:
a. Animmunosuppressant
b. Acarcinogen
c. Ateratogen
d. Anantiseizuremedication
ANS:C PTS:1
15. Immunomodulatorssuchasazathioprinemaycauseadelayedadv ersedrugreactionknownasaTypeDreactionbecausetheyareknown:
a. Teratogens
b. Carcinogens
c. Tocausehypersensitivityreactions
d. Hypothalamus-pituitary-adrenal(HPA)axissuppressants
ANS:B PTS:1
16. A24-yearoldmalereceivedmultiplefracturesinamotorvehicleaccidentthatrequir edsignificantamountsofopioidmedicationtotreathisHeisatriskforType adversedrugreactionwhenhenolongerrequirestheopioids.
a. A
b. C
c. E
d. G
ANS:C PTS:1
17. DrugsthatmaycauseaTypeEadversedrugreactioninclude:
a. Betablockers
b. Immunomodulators
c. Antibiotics
d. Oralcontraceptives
ANS:A PTS:1
18. UnexpectedfailureofdrugtherapyisaType adversedrugreaction,commonlycausedby .
a. B;cytotoxichypersensitivity
b. B;idiosyncraticresponse
c. C;cumulativeeffectsofdrug
d. F;drug-druginteraction
ANS:D PTS:1
19. Clopidogreltreatmentfailuremayoccurwhenitiscoadministeredwithomeprazole,knownasaType adversedrug
a. A
b. C
c. E
d. F
ANS:D PTS:1
MULTIPLECHOICE
1. Principlesofprescribingforolderadultsinclude:
A. Avoidingprescribinganynewerhighcostmedications
B. Startingatalowdoseandincreasingt hedoseslowly
C. Keepingtotaldoseatlowertherapeut icrange
D. Alloftheabove
ANS:B PTS:1
2. Sadieisa90-yearoldpatientwhorequiresanewWhatchangesindrugdistributionwithagin gwouldinfluenceprescribingforSadie?
A. Increasedvolumeofdistribution
B. Decreasedlipidsolubility
C. Decreasedplasmaproteins
D. Increasedmuscletofatratio
ANS:C PTS:1
3. Glenisan82yearoldwhoneedstobeprescribedWhatchangesineliminati onshouldbetakenintoconsiderationwhenprescribingforGlen?
A. IncreasedGFRwillrequirehigherdos esofsomerenallyexcreteddrugs
B. Decreasedtubularsecretionofmedic ationwillrequiredosageadjustments
C. Thinskinwillcauseincreasedelimina tionviasweat
D. Decreasedlungcapacitywillleadtom easurabledecreasesinlungexcretio nofdrugs
ANS:B PTS:1
4. Amedicationreviewofanelderlyperson’smedicationsinvolves:
B. Havingthepatientbringalloftheirpre scription,over-thecounter,andherbalmedicationtothe visit
C. Askingwhatotherprovidersarewritin gprescriptionsforthem
D. Alloftheabove
ANS:D PTS:1
5. Stepstoavoidpolypharmacyinclude:
A. Prescribingtwoorfewerdrugsfromea chdrugclass
B. Reviewingacompletedrughistoryev ery12to18months
C. Encouragingtheelderlypatienttocoo rdinatetheircarewithalloftheirprovi ders
D. Evaluatingforduplicationsindrugthe rapyanddiscontinuinganyduplicatio ns
ANS:D PTS:1
6. Robertisa72yearoldwhohashypertensionandHeisatriskforcommonme dicationpracticesseenintheelderlyincluding:
A. Useofanotherperson’smedications
B. Hoardingmedications
C. Changinghismedicationregimenwit houttellinghisprovider
D. Alloftheabove
ANS:D PTS:1
7. Toimprovepositiveoutcomeswhenprescribingfortheelderlythenursepr actitionershould:
A. Assesscognitivefunctioningintheeld er
B. Encouragethepatienttotakeaweekl y“drugholiday”tokeepdrugcostsdo wn
C. Encouragethepatienttocutdrugsinh alfwithaknifetolowercosts
D. Alloftheabove
ANS:A PTS:1
8. Whenanelderlydiabeticpatientisconstipatedthebesttreatmentoptionsi nclude:
A. Mineraloil
B. Bulkforminglaxativessuchaspsyllium
C. Stimulantlaxativessuchassenna
D. Stoolsoftenerssuchasdocusate
ANS:D PTS:1
9. Deltaisan88yearoldwhohasmildWhatguidelinesshouldbefollowedwhe nprescribingpainmanagementforDelta?
A. Keepthedoseofoxycodonelowtopre ventdevelopmentoftolerance
B. Acetaminophenisthefirstlinedrugofchoice
C. AvoidprescribingNSAIDs
D. Addinashortactingbenzodiazepineforasynergist iceffectonpain
ANS:B PTS:1
10. RobertiscomplainingofpoorMedicationsthatmaycontributetosle epproblemsintheelderlyinclude:
A. Diuretics
B. Trazodone
C. Clonazepam
D. Levodopa
ANS:A PTS:1
Chapter 11. ContactDermatitis
MULTIPLECHOICE
1. Whenchoosingatopicalcorticosteroidcreamtotreatdiaperdermatitis,th eidealmedicationwouldbe:
a. Intermediatepotencycorticosteroidointment(Kenalog)
b. Acombinationofacorticosteroidandanantifungal(Lotrisone)
c. Alowpotencycorticosteroidcreamappliedsparingly(hydrocortiso ne1%)
d. Ahighpotencycorticosteroidcream(DiproleneAF)
ANS:C PTS:1
2. Topicalimmunomodulatorssuchaspimecrolimus(Elidel)ortacrolimus(P rotopic)areusedfor:
a. Short-termorintermittenttreatmentofatopicdermatitis
b. Topicaltreatmentoffungalinfections(Candida)
c. Chronic,inflammatoryseborrheicdermatitis
d. Recalcitrantnodularacne
ANS:A PTS:1
3. Long-termtreatmentofmoderateatopicdermatitisincludes:
a. Topicalcorticosteroidsandemollients
b. Topicalcorticosteroidsalone
c. Topicalantipruritics
d. Oralcorticosteroidsforexacerbationsofatopicdermatitis
ANS:A PTS:1
4. Severecontactdermatitiscausedbypoisonivyorpoisonoakexposureofte nrequirestreatmentwith:
a. Topicalantipruritics
b. Oralcorticosteroidsfor2to3weeks
c. Thicklyappliedtopicalintermediate-dosecorticosteroids
d. Isolationofthepatienttopreventspreadofthedermatitis
ANS:B PTS:1
5. Whenapatienthascontactdermatitis,wetdressingswithDomeborosolut ionareusedfor:
a. Cleaningtheweepingareaofdermatitis
b. Bathingthepatienttopreventinfection
c. Reliefofinflammation
d. Providingabarrierlayertoprotectthesurroundingskin
ANS:C PTS:1
TopicalcorticosteroidsareusedtotreatseveralTopicalcorticosteroidsar econtraindicatedfortreatmentofwhichofthefollowingconditions?
a. Psoriasis c. Eczema
b. Contactdermatitis d. Rosacea
ANS:D PTS:1
7. AtopicalcorticosteroidmaybeusedtoWhatinstructionmustbegiventoap atientforwhomatopicalcorticosteroidisprescribedfortreatmentoffacial eczema?
8. “Becarefulnottogetanyofthemedicationinyour”
9. “Stayoutofstrongsunlightwhileusingthe”
10. “Putathinlayerofmedicationononceadayjustbeforeyougoto”
11. “Checkbeforeyouuseitthatthemedicationislabeledfluorinated.”
ANS:A PTS:1
8. GroupItopicalcorticosteroidsmaycauseadverseApatientwhoisbeingtre atedwithagroupItopicalcorticosteroidmustbecloselymonitoredfor a . increasedhepaticenzymes. c. epithelialkeratopathy.
b HPAsuppression. d. bonemarrowdepression.
ANS:B PTS:1
9. Treatmentwithgentamicin(Garamycin)maypresentdisadvantagesfort heArenalpatient’suseofthedrugmayleadto
10. deteriorationofthe
11. riskofliverdamagesecondarytosystemic
12. occurrenceof
13.
ANS:D PTS:1
9. Thetopicalantiviraldrugacyclovir(Zovirax)isusedtotreatseveraldiffere ntWhichofthefollowingconditionsisanunlabeleduseforacyclovir(Zovira x)?
a. Herpesgenitalis
b . HerpessimplexvirustypesIandII
ANS:C PTS:1
c. Herpeslabialis
d. Epstein-Barrvirus
10. Lindane(Kwell,Scabene)isusedtotreatseveralForwhichdisorderi stheuseoflindane(Kwell,Scabene)contraindicated?
a. Pediculosispubis
b. Sarcoptesscabiei
c. Scabies
d. Seizures
ANS:D PTS:1
15. Scabiestreatmentfora4-year-oldchildincludesaprescriptionfor:
a. Permethrin5%creamappliedfromtheneckdown
b. Pyrethrinlotion
c. Lindane1%shampoo
d. Alloftheabove
ANS:A PTS:1
16. VanessahasbeenHereducationwouldinclude:
a. Sheshouldapplythescabiestreatmentcreamforanhourandwashit off
b. Scabiesmayneedtoberetreatedinaweekafterinitialtreatment
c. Allmembersofthehouseholdandclosepersonalcontactsshouldbe treated
d. Malathionisflammableandsheshouldtakecareuntilthesolutiondri es
ANS:C PTS:1
17. Catherinehasheadliceandhermotherisaskingaboutwhatproduct sareavailablethatarenotTheonlynon-neurotoxinheadlicetreatmentis:
a. Permethrin1%(Nix)
b. Lindaneshampoo
c. Malathion(Ovide)
d. Benzoylalcohol(Ulesfia)
ANS:D PTS:1
Pharmacotherapeutics for Advanced Practice test bank,